Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definitions
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Base estimates & calculations
1.3.1 Base year calculation
1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
1.5.1 Primary sources
1.5.2 Data mining sources
Chapter 2 Executive Summary
2.1 Industry 3600 synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Increasing incidence of glioblastoma
3.2.1.2 Rising awareness and early diagnosis of disease
3.2.1.3 Increase in the number of R&D activities
3.2.2 Industry pitfalls & challenges
3.2.2.1 High recurrence rate of glioblastoma even after treatment
3.2.2.2 High cost of treatment
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Pipeline analysis
3.6 Porter’s analysis
3.7 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategic dashboard
Chapter 5 Market Estimates and Forecast, By Treatment, 2021 - 2032 ($ Million)
5.1 Key trends
5.2 Surgery
5.3 Radiation therapy
5.4 Chemotherapy
5.5 Targeted therapy
5.6 Tumor treating field therapy
5.7 Immunotherapy
Chapter 6 Market Estimates and Forecast, By Drug Class, 2021 - 2032 ($ Million)
6.1 Key trends
6.2 Temozolomide
6.3 Bevacizumab
6.4 Lomustine
6.5 Carmustine wafers
Chapter 7 Market Estimates and Forecast, By Dosage Form, 2021 - 2032 ($ Million)
7.1 Key trends
7.2 Oral
7.3 Parenteral
Chapter 8 Market Estimates and Forecast, By Gender, 2021 - 2032 ($ Million)
8.1 Key trends
8.2 Male
8.3 Female
Chapter 9 Market Estimates and Forecast, By End-use, 2021 - 2032 ($ Million)
9.1 Key trends
9.2 Hospitals
9.3 Cancer treatment centers
9.4 Ambulatory surgical centers
9.5 Other end-users
Chapter 10 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Million)
10.1 Key trends
10.2 North America
10.2.1 U.S.
10.2.2 Canada
10.3 Europe
10.3.1 Germany
10.3.2 UK
10.3.3 France
10.3.4 Spain
10.3.5 Italy
10.3.6 Netherlands
10.3.7 Rest of Europe
10.4 Asia Pacific
10.4.1 Japan
10.4.2 China
10.4.3 India
10.4.4 Australia
10.4.5 South Korea
10.4.6 Rest of Asia Pacific
10.5 Latin America
10.5.1 Brazil
10.5.2 Mexico
10.5.3 Rest of Latin America
10.6 Middle East and Africa
10.6.1 South Africa
10.6.2 Saudi Arabia
10.6.3 UAE
10.6.4 Rest of Middle East and Africa
Chapter 11 Company Profiles
11.1 Amgen Inc.
11.2 Amneal Pharmaceuticals
11.3 Curtana Pharmaceuticals
11.4 Denovo Biopharma
11.5 Eisai Co. Ltd. (Gliadel)
11.6 F. Hoffmann La Roche Ltd (Genetech USA)
11.7 Karyopharm Therapeutics
11.8 Merck & Co. Inc.
11.9 Novocure GmbH
11.10 Pfizer, Inc.
11.11 Sumitomo Dainippon Pharma Co., Ltd.
11.12 Sun Pharmaceutical Industries Ltd.
11.13 Teva Pharmaceutical Industries
